Healthcare / BiotechnologyShanghai
$6.11
+0.03 (+0.49%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-228.8M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
19/100
F
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.0B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-16.7%
↓Gross Margin
-14.5%
↓Debt/Equity
0.30
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-2.8%
FCF CAGR
—
FCF margin
-85.5%
FCF / Net income
0.97x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $267.7M · net income $-235.1M · FCF $-228.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $267.7M | $267.7M | $248.1M | $204.8M | $291.3M |
| Net Income | $-235.1M | $-235.1M | $-321.8M | $-127.9M | $39.3M |
| EBITDA | $-127.4M | $-127.4M | $-219.9M | $-114.4M | $69.5M |
| EPS | -0.37 | -0.37 | -0.50 | -0.20 | 0.07 |
| Gross Margin | -14.5% | -14.5% | -37.8% | -6.4% | 44.4% |
| Operating Margin | -77.0% | -77.0% | -105.3% | -76.3% | 5.2% |
| Net Margin | -87.8% | -87.8% | -129.7% | -62.5% | 13.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.30 | 0.30 | 0.12 | 0.09 | 0.04 |
| Current Ratio | 1.28 | 1.28 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-228.8M | $-228.8M | $-228.5M | $-637.2M | $-463.0M |
| Returns | |||||
| ROE | -16.7% | -16.7% | -18.5% | -6.2% | 1.8% |
| Valuation | |||||
| P/E | — | — | — | — | 265.68 |
| EV/EBITDA | — | — | — | — | 133.47 |
| P/B | 2.76 | 2.76 | 1.71 | 2.65 | 4.80 |
| Growth & Yield | |||||
| Revenue Growth | 7.9% | 7.9% | 21.2% | -29.7% | — |
| EPS Growth | 25.6% | 25.6% | -149.7% | -406.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+5.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.50 → -0.37
Residual
+5.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.